Exploring rutinoside's impact on inflammation in a rat knee OA model induced by monosodium iodoacetate (MIA)

Abstract

Link of Video Abstract: https://youtu.be/Dl8sYvPfd6o Introduction: Osteoarthritis (OA) is a common joint disease characterized by persistent inflammation and cartilage breakdown. Monosodium iodoacetate (MIA) is often used to generate OA in rats. This study aims to explore the anti-inflammatory benefits of rutinoside, a natural flavonoid glycoside, in rats with MIA-induced knee OA. Methods: The male Wistar rats were divided into five groups (n = 6) and randomly allocated to one of five treatments: control, OA, rutinoside, glucosamine sulfate, and sodium diclofenac-treated group. 3 mg of monosodium iodoacetate (MIA) was injected intra-articularly into the knee joints of rats to induce osteoarthritis. Rutinoside, glucosamine sulfate, and sodium diclofenac were given daily for four weeks. Body weight, joint swelling, knee bend score, interleukin-1 (IL-1) levels, interleukin-8 (IL-8) levels, and C-terminal telopeptide type II collagen (CTX-II) levels were all assessed. Result: Rutinoside significantly decreased body weight loss, joint edema, and knee bend test scores compared to the untreated OA group. Furthermore, rutinoside was equally effective as glucosamine sulfate and sodium diclofenac in these parameters. The rutinoside, glucosamine sulfate, and sodium diclofenac groups had significantly lower IL-1, IL-8, and CTX-II levels than the untreated OA group. Conclusion: Rutinoside reduced inflammatory responses, lowered joint edema, and improved knee bend test scores in a rat model of MIA-induced osteoarthritis. Its efficacy in preventing illness was comparable to glucosamine sulfate and sodium diclofenac. More study is needed to better understand rutinoside's underlying mechanisms and long-term consequences for treating osteoarthritis.